Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alnylam Ends Relationship With Sirna Owner Merck

This article was originally published in The Pink Sheet Daily

Executive Summary

RNAi firm Alnylam terminated the relationship “to protect our intellectual property,” COO Greene tells “The Pink Sheet” DAILY.

You may also be interested in...



Regulus Signs Potential $600 Million MicroRNA Collaboration With GSK

Firms will co-develop microRNA targeted therapeutics in inflammation and immunology.

Regulus Signs Potential $600 Million MicroRNA Collaboration With GSK

Firms will co-develop microRNA targeted therapeutics in inflammation and immunology.

Alnylam Expands Asian Presence With RNAi License To Japan's GeneDesign

Alnylam Pharmaceuticals has granted Osaka, Japan-based GeneDesign a nonexclusive license to provide small interfering RNA research products and services using Alnylam's Kreutzer-Limmer patent estate, the companies announced Oct. 3

Related Content

Topics

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel